USFDA completes cGMP inspection at Cipla's manufacturing facility in Indore
Cipla Limited has notified that the United States Food and Drug Administration (USFDA) conducted a 'current Good Manufacturing Practices' (cGMP) inspection at its Pithampur manufacturing facility from 6th – 17th February, 2023, via an exchange filing. The company received 8 inspectional observations in Form 483 at the end of the inspection.
United States Drug Administration Cipla Limited United States Food Good Manufacturing Practice Listing Obligations
Source: freepressjournal.in